A series of 5‐[(phenethylamino)methyl]pyrimidine‐2,4‐diamines were assessed in silico as potential inhibitors of Plasmodium falciparum dihydrofolate reductase (PfDHFR), synthesised and tested for inhibitory activity against PfDHFR in vitro. The compounds displayed promising… Click to show full abstract
A series of 5‐[(phenethylamino)methyl]pyrimidine‐2,4‐diamines were assessed in silico as potential inhibitors of Plasmodium falciparum dihydrofolate reductase (PfDHFR), synthesised and tested for inhibitory activity against PfDHFR in vitro. The compounds displayed promising inhibitory activity against both wild‐type (Ki 1.3–243 nM) and quadruple mutant (Ki 13–208 nM) PfDHFR in the biochemical enzyme assay, but were less potent in the whole‐cell P. falciparum assay (IC50(TM4/8.2) 0.4–28 μM; IC50(V1S) 3.7–54 μM). Further investigation into the pharmacokinetic properties of these compounds may guide the development of more potent analogues.
               
Click one of the above tabs to view related content.